Alphabet's Calico Life Sciences inked an exclusive licensing deal with Mabwell Bioscience for up to $596 million targeting interleukin-11 therapeutics. Calico gains global rights, excluding Greater China, to 9MW3811, a monoclonal antibody in clinical trials for idiopathic pulmonary fibrosis and age-related diseases. The agreement advances Calico's mission to develop biology-of-aging interventions and complements its existing partnerships including AbbVie and the Broad Institute. Mabwell’s investigational new drug application is active with the FDA, enabling possible U.S. clinical development under Calico’s stewardship.